Cited by 277HIV/AIDS drug development and treatmentHIV/AIDS Research and InterventionsHIV Research and Treatment

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Abacavir-Lamivudine-Zidovudine vs Indinavir-Lamivudine-Zidovudine in Antiretroviral-Naive HIV-Infected Adults<SUBTITLE>A Randomized Equivalence Trial</SUBTITLE>

Staszewski, Schlomo·2001·JAMA

Open this paper in CoChat — free account

Abstract

Context Abacavir, a nucleoside analogue, has demonstrated suppression of human immunodeficiency virus (HIV) replication alone and in combination therapy. However, the role of abacavir in a triple nucleoside combination regimen has not been evaluated against a standard protease inhibitor-containing regimen for initial antiretroviral treatment. Objective To evaluate antiretroviral equivalence and safety of an abacavir-lamivudine-zidovudine regimen compared with an indinavir-lamivudine-zidovudine regimen. Design and setting A multicenter, phase 3, randomized, double-blind trial with an enrollment period from August 1997 to June 1998, with follow-up through 48 weeks at 73 clinical research units in the United States, Canada, Australia, and Europe. Patients Five hundred sixty-two antiretroviral-naive, HIV-infected adults with a plasma HIV RNA level of at least 10 000 copies/mL and a CD4 cell count of at least 100 x 10(6)/L. Interventions Patients were stratified by baseline HIV RNA level and randomly assigned to receive a combination tablet containing 150 mg of lamivudine and 300 mg of zidovudine twice daily plus either 300 mg of abacavir twice daily and indinavir placebo or 800 mg of indinavir every 8 hours daily plus abacavir placebo. After 16 weeks, patients with confirmed HIV RNA levels greater than 400 copies/mL were eligible to continue receiving randomized treatment or receive open-label therapy. Main outcome measure Virologic suppression, defined as HIV RNA concentration o…

Integrity signals

Registry

Crossref · 10.1001/jama.285.9.1155

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-12_part_2-199806151-00003 · Cited by 5,197
1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults
Castro, K. G., Ward, J., Slutsker, L., Buehler, J. W., Jaffe, H. W., Berkelman, R. L., & Curran, J. W. (1993) · Clinical Infectious Diseases · doi:10.1093/clinids/17.4.802 · Cited by 4,347
A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less
Hammer, S. M., Squires, K., Hughes, M. D., Grimes, J. M., Demeter, L. M., Currier, J. S., Eron, J. J., Feinberg, J., Balfour, H. H., Deyton, L., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709113371101 · Cited by 2,638
Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy
Gulick, R. M., Mellors, J. W., Havlir, D. V., Eron, J. J., Gonzalez, C. J., McMahon, D. K., Richman, D. D., Valentine, F. T., Jonas, L., Meibohm, A. R., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709113371102 · Cited by 1,883
Empirical evidence of design-related bias in studies of diagnostic tests.
Lijmer, J. G. (1999) · JAMA · doi:10.1001/jama.282.11.1061 · Cited by 1,861
British HIV Association guidelines for the treatment of HIV‐1‐infected adults with antiretroviral therapy 2008
Gazzard, B., & on behalf of the BHIVA Treatment Guidelines Writing Group (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2008.00636.x · Cited by 1,090
Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.
Carr, A., Samaras, K., Chisholm, D. J., & Cooper, D. A. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03391-1 · Cited by 1,065
Antiretroviral Therapy in Adults
Carpenter, C. C. J., Cooper, D. A., Fischl, M. A., Gatell, J. M., Gazzard, B., Hammer, S. M., Hirsch, M., Jacobsen, D. M., Katzenstein, D. A., Montaner, J. S. G., et al. (2000) · JAMA · doi:10.1001/jama.283.3.381 · Cited by 1,007
Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults
Staszewski, S., Morales-Ramirez, J. O., Tashima, K. T., Rachlis, A., Skiest, D. J., Stanford, J., Stryker, R., Johnson, P. C., Labriola, D., Farina, D., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912163412501 · Cited by 993
Self-citation
1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults
(1993) · JAMA · doi:10.1001/jama.1993.03500040022009 · Cited by 964
Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study
Ledergerber, B., Egger, M., Opravil, M., Telenti, A., Hirschel, B. J., Battegay, M., Vernazza, P., Sudre, P., Flepp, M., Furrer, H., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)01122-8 · Cited by 906
Guidelines for Meta-analyses Evaluating Diagnostic Tests
Irwig, L., Tosteson, A. N. A., Gatsonis, C., Lau, J., Colditz, G. A., Chalmers, T. C., & Mosteller, F. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-120-8-199404150-00008 · Cited by 754
Mechanisms of Virologic Failure in Previously Untreated HIV-Infected Patients From a Trial of Induction-Maintenance Therapy
Descamps, D. (2000) · JAMA · doi:10.1001/jama.283.2.205 · Cited by 371
Potential factors affecting adherence with HIV therapy
Mehta, S., Moore, R. D., & Graham, N. M. H. (1997) · AIDS · doi:10.1097/00002030-199714000-00002 · Cited by 332
Drug Susceptibility in HIV Infection After Viral Rebound in Patients Receiving Indinavir-Containing Regimens
Havlir, D. V. (2000) · JAMA · doi:10.1001/jama.283.2.229 · Cited by 297
Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy
Raboud, J., Montaner, J. S. G., Conway, B., Rae, S., Reiss, P., Vella, S., Cooper, D. A., Lange, J. M. A., Harris, M., Wainberg, M. A., et al. (1998) · AIDS · doi:10.1097/00002030-199813000-00008 · Cited by 259
Simultaneous vs Sequential Initiation of Therapy With Indinavir, Zidovudine, and Lamivudine for HIV-1 Infection
Gulick, R. M., Mellors, J. W., Havlir, D. V., Eron, J. J., Gonzalez, C. J., McMahon, D. K., Jonas, L., Meibohm, A. R., Holder, D., Schleif, W. A., et al. (1998) · JAMA · doi:10.1001/jama.280.1.35 · Cited by 234
Points to consider on switching between superiority and non‐inferiority
Committee for Proprietary Medicinal Products (CPMP) (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2001.01397-3.x · Cited by 234
Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89
Faletto, M. B., Miller, W. H., Garvey, E. P., Clair, M. H. S., Daluge, S. M., & Good, S. S. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.5.1099 · Cited by 224
The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir
Kempf, D. J., Rode, R. A., Xu, Y., Sun, E., Heath-Chiozzi, M. E., Valdes, J. M., Japour, A. J., Danner, S. A., Boucher, C. A., Molla, A., et al. (1998) · AIDS · doi:10.1097/00002030-199805000-00001 · Cited by 222
Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89
Tisdale, M., Alnadaf, T., & Cousens, D. J. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.5.1094 · Cited by 221
Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing
Larder, B. A., Kohli, A., Kellam, P., Kemp, S. D., Kronick, M. N., & Henfrey, R. D. (1993) · Nature · doi:10.1038/365671a0 · Cited by 198
British HIV Association (BHIVA) guidelines for the treatment of HIV‐infected adults with antiretroviral therapy (2006)
Gazzard, B. (2006) · HIV Medicine · doi:10.1111/j.1468-1293.2006.00424.x · Cited by 188
6-year experience of prenatal diagnosis in an unselected population in Oxford, UK
Boyd, P. A., Chamberlain, P. F., & Hicks, N. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03202-4 · Cited by 160
Resistance Profile of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitor Abacavir (1592U89) after Monotherapy and Combination Therapy
Harrigan, P. R., Stone, C., Griffin, P., Nájera, I., Bloor, S., Kemp, S. D., Tisdale, M., Larder, B. A., & the CNA2001 Investigative Group (2000) · The Journal of Infectious Diseases · doi:10.1086/315317 · Cited by 159
Antiretroviral Therapy in Adults
WISE, B. V. (1996) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.1996.tb00672.x · Cited by 137
HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy
Miller, V., Ait‐Khaled, M., Stone, C., Griffin, P. C., Mesogiti, D., Cutrell, A. G., Harrigan, R., Staszewski, S., Katlama, C., Pearce, G. L., et al. (2000) · AIDS · doi:10.1097/00002030-200001280-00012 · Cited by 132
Self-citation
Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients
Casado, J. L., Pérez-Elı́as, M. J., Antela, A., Sabido, R., Martí-Belda, P., Dronda, F., Blázquez, J., & Quereda, C. (1998) · AIDS · doi:10.1097/00002030-199811000-00005 · Cited by 124
Hit HIV-1 hard, but only when necessary
Harrington, M., & Carpenter, C. C. J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02388-6 · Cited by 122
The case for confidence intervals in controlled clinical trials
Borenstein, M. (1994) · Controlled Clinical Trials · doi:10.1016/0197-2456(94)90036-1 · Cited by 86
A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I)
Squires, K., Gulick, R. M., Tebas, P., Santana, J., Mulanovich, V. E., Clark, R. A., Yangco, B. G., Marlowe, S. I., Wright, D. J., Cohen, C. J., et al. (2000) · AIDS · doi:10.1097/00002030-200007280-00015 · Cited by 85
A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects
Staszewski, S., Katlama, C., Harrer, T., Massip, P., Yéni, P., Cutrell, A. G., Tortell, S. M., Harrigan, R., Steel, H. M., Lanier, R., et al. (1998) · AIDS · doi:10.1097/00002030-199816000-00001 · Cited by 85
Self-citation
Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults
Saag, M. S., Sönnerborg, A. B., de Torres, R. A., Lancaster, D. J., Gazzard, B., Schooley, R. T., Romero, C., Kelleher, D. L., Spreen, W. R., & LaFon, S. W. (1998) · AIDS · doi:10.1097/00002030-199816000-00002 · Cited by 84
Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies
Maguire, M. F., Gartland, M., Moore, S., Hill, A. M., Tisdale, M., Harrigan, R., & Kleim, J. (2000) · AIDS · doi:10.1097/00002030-200006160-00017 · Cited by 69
Suppression of Plasma Virus Load below the Detection Limit of a Human Immunodeficiency Virus Kit Is Associated with Longer Virologic Response than Suppression below the Limit of Quantitation
Raboud, J., Rae, S. L., Hogg, R. S., Yip, B., Sherlock, C. H., Harrigan, P. R., O'Shaughnessy, M. V., & Montaner, J. S. G. (1999) · The Journal of Infectious Diseases · doi:10.1086/314998 · Cited by 42
Amprenavir in Combination with Lamivudine and Zidovudine versus Lamivudine and Zidovudine Alone in HIV-1-Infected Antiretroviral-Naive Adults
Goodgame, J., Pottage, J. C., Jablonowski, H., Hardy, W. D., Stein, A. J., Fischl, M. A., Morrow, P., Feinberg, J., Brothers, C. H., Vafidis, I., et al. (2000) · Antiviral Therapy · doi:10.1177/135965350000500306 · Cited by 39
Combined ultrasound biometry, serum markers and age for Down syndrome risk estimation
Bahado-Singh, R., Öz, A. U., Gomez, K. J., Hunter, D., Copel, J. A., Baumgarten, A., & Mahoney, M. J. (2000) · Ultrasound in Obstetrics and Gynecology · doi:10.1046/j.1469-0705.2000.00071.x · Cited by 31
Considerations in the choice of protease inhibitor-sparing regimens in initial therapy for HIV-1 infection
Moyle, G. J. (2000) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200002000-00004 · Cited by 17

Flagged first, then by citations

Sorted by citations

Reporting of Noninferiority and Equivalence Randomized Trials: Extension of the CONSORT 2010 Statement
Piaggio, G., Elbourne, D. R., Pocock, S. J., Evans, S. J. W., Altman, D. G., & CONSORT Group, F. T. (2012) · JAMA · doi:10.1001/jama.2012.87802 · Cited by 2,428
HLA-B*5701 Screening for Hypersensitivity to Abacavir
Mallal, S. A., Phillips, E. J., Carosi, G., Molina, J., Workman, C., Tomažič, J., Jägel-Guedes, E., Rugină, S., Козырев, О. А., Cid, J. F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706135 · Cited by 1,834
British HIV Association guidelines for the treatment of HIV‐1‐infected adults with antiretroviral therapy 2008
Gazzard, B., & on behalf of the BHIVA Treatment Guidelines Writing Group (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2008.00636.x · Cited by 1,090
Treatment for Adult HIV Infection
Hammer, S. M., Saag, M. S., Schechter, M., Montaner, J. S. G., Schooley, R. T., Jacobsen, D. M., Thompson, M., Carpenter, C. C. J., Fischl, M. A., Gazzard, B., et al. (2006) · JAMA · doi:10.1001/jama.296.7.827 · Cited by 1,034
Treatment for Adult HIV Infection
Yéni, P., Hammer, S. M., Hirsch, M., Saag, M. S., Schechter, M., Carpenter, C. C. J., Fischl, M. A., Gatell, J. M., Gazzard, B., Jacobsen, D. M., et al. (2004) · JAMA · doi:10.1001/jama.292.2.251 · Cited by 780

See all 277

Authors: Staszewski, S.
Affiliations: Goethe University Frankfurt (DE)
Corresponding author: Staszewski, Schlomo
Venue: JAMA
Publisher: American Medical Association (AMA)
Published: 2001-03-07
Volume: 285
Issue: 9
Pages: 1155
ISSN: 0002-9955 (ISSN-L)
0098-7484
DOI: 10.1001/jama.285.9.1155
OpenAlex: W2129710521
Cited by: 277
References: 38
Citations by year: 2026: 1 · 2023: 1 · 2022: 2 · 2020: 2 · 2019: 2 · 2018: 2 · 2017: 2 · 2016: 5 · 2015: 5 · 2014: 5 · 2013: 10 · 2012: 6
FWCI: 31.43
Type: journal article
Language: en
Open access: closed
Locations: JAMA (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
Keywords: abacavir, indinavir, lamivudine, zidovudine, HIV infection, antiretroviral-naive patients, triple-drug combination therapy, nucleoside reverse transcriptase inhibitors, protease inhibitors, viral suppression, treatment safety, drug interactions, adverse events, CD4 count, HIV RNA
MeSH terms: Abacavir, Adult, Aged, Double-Blind Method, Drug Resistance, Microbial, Female, Genotype, HIV, Humans, Male, Middle Aged, Mutation, Therapeutic Equivalency, Zidovudine, Dideoxynucleosides, HIV Infections, Survival Analysis, HIV Protease Inhibitors, CD4 Lymphocyte Count, Reverse Transcriptase Inhibitors, Lamivudine, Anti-HIV Agents, Indinavir, Viral Load, Antiretroviral Therapy, Highly Active, HIV Reverse Transcriptase

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Abacavir-Lamivudine-Zidovudine vs Indinavir-Lamivudine-Zidovudine in Antiretroviral-Naive HIV-Infected Adults<SUBTITLE>A Randomized Equivalence Trial</SUBTITLE>

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks